The identification of GW6471 as the first potent, dual PPARα/γ antagonist (Figures 4E and 4F) provided the opportunity to test the hypothesis that concurrent antagonism of both PPARα and γ could be an effective mesothelioma treatment. This evidence concerns the gene PPARA and mesothelioma.